140111-52-0
Chemical Structure
Epibatidine
- CAS No.: 140111-52-0
- Formula:C11H13ClN2
- Molecular Weight:208.69
InChIKey: NLPRAJRHRHZCQQ-IVZWLZJFSA-N
SMILES: ClC1=NC=C([C@@H]2[C@]3([H])N[C@](CC3)([H])C2)C=C1
Biological Activity: Epibatidine is a nicotinic acetylcholine receptor (nAChR) agonist, with an IC50 of 70 pM, a Ki of 43 pM for rat nAChR, a Kd range of 1.5-60 nM for human α7 nAChR, a Kd of 15 nM for rat α4β2 nAChR, and a Kd of 0.5 μM for rat α3β4 nAChR. Epibatidine selectively activates central nAChRs and binds to muscarinic acetylcholine receptors (mAChR). It is used in research on pain, Alzheimer's disease, Parkinson's disease, and schizophrenia-related pain[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Epibatidine | Epibatidine is a nicotinic acetylcholine receptor (nAChR) agonist, with an IC50 of 70 pM, a Ki of 43 pM for rat nAChR, a Kd range of 1.5-60 nM for human α7 nAChR, a Kd of 15 nM for rat α4β2 nAChR, and a Kd of 0.5 μM for rat α3β4 nAChR. Epibatidine selectively activates central nAChRs and binds to muscarinic acetylcholine receptors (mAChR). It is used in research on pain, Alzheimer's disease, Parkinson's disease, and schizophrenia-related pain. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Qian C, et al. Epibatidine is a nicotinic analgesic. European journal of pharmacology. 1993 Dec 21;250(3):R13-4.
- [2]. Thompson AJ, et al. The binding orientation of epibatidine at α7 nACh receptors. Neuropharmacology. 2017 Apr;116:421-428. [Content Brief]
- [3]. Ulrich YM, et al. A comparison of multiple injections versus continuous infusion of nicotine for producing up-regulation of neuronal [3H]-epibatidine binding sites. Neuropharmacology. 1997 Aug;36(8):1119-25.
- [4]. Salehi B, et al. Epibatidine: A Promising Natural Alkaloid in Health. Biomolecules. 2018 Dec 23;9(1):6.
- [5]. Daly JW, et al. Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Nat Prod Rep. 2000 Apr;17(2):131-5.
- [6]. Khan IM, et al. Epibatidine binding sites and activity in the spinal cord. Brain research. 1997 Apr 11;753(2):269-82.
